Castle Biosciences (CSTL) Income from Continuing Operations (2018 - 2026)

Castle Biosciences has disclosed Income from Continuing Operations across 9 years of filings, most recently posting 14522000.0 for Q1 2026.

• Income from Continuing Operations for Q1 2026 came in at 14522000.0, up 43.82% year-over-year; the trailing twelve-month figure through Mar 2026 was 12832000.0 (down 153.15% YoY), and the FY2025 annual result was 24158000.0, down 232.41% from the prior year.
• Income from Continuing Operations came in at 14522000.0 for Q1 2026 at Castle Biosciences, down from 2332000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 9590000.0 in Q4 2024 to a low of 29204000.0 in Q1 2023.
• The 5-year median for Income from Continuing Operations is 2580000.0 (2023), against an average of 8531705.88.
• Across the five-year window, Income from Continuing Operations slumped 1039.38% in 2023 and soared 471.71% in 2024, its largest moves.
• Castle Biosciences' Income from Continuing Operations stood at 20618000.0 in 2022, then surged by 87.49% to 2580000.0 in 2023, then jumped by 471.71% to 9590000.0 in 2024, then sank by 124.32% to 2332000.0 in 2025, then sank by 522.73% to 14522000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 14522000.0 (Q1 2026), 2332000.0 (Q4 2025), and 501000.0 (Q3 2025), per Business Quant data.